A Phase 2 Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer

Full Title

Combination targeted and Hormonal treAtMEnt of Low-gradE serous Ovarian cancer in the upfroNt setting (CHAMELEON)

Purpose

Researchers want to see how well a new combination of drugs works to treat low-grade serous ovarian cancer. The drugs are avutometinib, defactinib, and letrozole. The people in this study have ovarian cancer that cannot be completely removed with surgery.

Avutometinib and defactinib work against cancer by blocking a protein (the kinase protein) that plays a role in cancer growth. Letrozole blocks the body from producing estrogen, a hormone that can cause cancer growth. All three medications are taken orally (by mouth).

Contact

For more information and to see if you can join this study, please call Dr. Rachel Grisham’s office at 646-888-4653.